<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02373917</url>
  </required_header>
  <id_info>
    <org_study_id>Lung-RND-001</org_study_id>
    <nct_id>NCT02373917</nct_id>
  </id_info>
  <brief_title>Characterization of Methylation Patterns in Lung Cancer</brief_title>
  <official_title>Characterization of Methylation Patterns in Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nucleix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nucleix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators will collect Blood,sputum and saliva samples for
      Characterization of Methylation Patterns in lung Cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lots of information about the relationship between changes in methylation patterns and
      various diseases are accumulated in recent years. Characterization of methylation changes
      that occur in cancer may contribute to the development of methods for early detection of
      cancer by detecting cancer cells in liquids. Early detection of such changes and their
      correlation examining different cancers may lead to a diagnostic tool for the early detection
      of cancers and improve the treatment of these patients. Detection by molecular analysis can
      be a sensitive method and non-invasive early diagnosis of the disease In this study the
      investigators will collect Blood,sputum and saliva samples for Characterization of
      Methylation Patterns in lung Cancer.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Anticipated">April 2021</completion_date>
  <primary_completion_date type="Anticipated">April 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterization of Methylation Patterns in lung Cancer</measure>
    <time_frame>two years</time_frame>
    <description>Collecting and analyzing samples</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">430</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>study group</arm_group_label>
    <description>patient who in the biopsy showed lung cancer</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>patient who in the biopsy showed not to have lung cancer</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      1. Blood samples

        2. Sputum samples

        3. saliva samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Participants who come to the medical center for the diagnosis of lung cancer.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with suspected lung tumor

        Exclusion Criteria:

          -  Patients who have active disease other than lung cancer during the sample collecting
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eilon Ganor, MD</last_name>
    <role>Study Director</role>
    <affiliation>Nucleix Ltd.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eilon Ganor, MD</last_name>
    <phone>9723-7674840</phone>
    <email>Elon@nucleix.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sha'are Tzedaek Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel Izbicki, MD</last_name>
      <email>izbicki@szmc.org.il</email>
    </contact>
    <investigator>
      <last_name>Gabriel Izbicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 22, 2015</study_first_submitted>
  <study_first_submitted_qc>February 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2015</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

